This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Telbermin

Roche Holding AG

Drug Names(s): RhVEGF, Topical VEGF

Description: Telbermin is a topical Recombinant Human Vascular Endothelial Growth Factor (VEGF). VEGF is a naturally occurring protein that ischemic tissues - tissues lacking oxygen - secrete. Research has shown that when VEGF is introduced to endothelial cells, it stimulates the development of new blood vessels.

Deal Structure: Telbermin was originally developed by Genentech.

In March 2009, Roche and Genentech announced that they signed a merger agreement under which Roche will acquire the outstanding publicly held interest in Genentech for US95.00 per share in cash, or a total payment of approximately US$46.8 billion to equity holders of Genentech other than Roche. The acquisition was completed on March 26, 2009.


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug